Application of medication therapy management-based “in-hospital assessment - home-based intervention” pharmaceutical care in patients with depression

Table 3 Comparison of Hamilton Depression Rating Scale score changes and clinical response rates between two groups of patients with depression

Indicator	Time point	Intervention group (n = 52)	Control group (n = 52)	t/χ2 value	P value
HAMD-17 score	Baseline	24.60 ± 3.90	24.30 ± 3.60	0.301	0.764
	3 months	16.20 ± 4.10	19.80 ± 3.90	4.472	< 0.001
	6 months	12.10 ± 4.20	17.40 ± 4.00	6.325	< 0.001
	9 months	8.50 ± 3.90	15.20 ± 4.10	8.142	< 0.001
Clinical response rate (≥ 50% reduction in HAMD-17 score)	3 months	20 (38.46)	10 (19.23)	4.983	0.026
	6 months	37 (71.15)	22 (42.31)	9.327	0.002
	9 months	43 (82.69)	27 (51.92)	12.045	0.001
Clinical remission rate (HAMD-17 score ≤ 7)	3 months	5 (9.62)	1 (1.92)	2.836	0.092
	6 months	22 (42.31)	5 (9.62)	14.286	< 0.001
	9 months	34 (65.38)	10 (19.23)	20.735	< 0.001
Cumulative relapse rate	3 months	1 (1.92)	3 (5.77)
	6 months	2 (3.85)	6 (11.54)	4.528	0.033
	9 months	5 (9.62)	12 (23.08)	6.992	0.008

Data are presented as mean ± SD or n (%).

HAMD-17: 17-item Hamilton Depression Rating Scale.